Compare F5 Inc (FFIV) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Johnson & Johnson — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 23.6× F5 Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Johnson & Johnson for 129 Days on average.
| FFIV | JNJ | |
|---|---|---|
Market Cap | $26.14B | $618.09B |
Volume | 503,146 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $469.79 | $278.43 |
52-Week Low | $223.99 | $186.00 |
Typical Hold Time | 38 Days | 129 Days |
Enterprise Value | $24.78B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $479.83, up 2.82% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and robust revenue growth, reaching $3.09 billion in 2025. Positive sentiment is driven by leadership in AI security and strategic partnerships, though valuation multiples like a P/E of 36.78 suggest premium pricing. Cash flow remains healthy with $268 million net inflow in 2025, supporting operational strength.
Outlook is cautiously optimistic with growth in AI and security markets offering upside, but risks include high valuation and competitive pressures. Analysts are mixed with a $416.60 consensus target below current price, indicating potential overvaluation. Investors should weigh solid fundamentals against elevated multiples for balanced risk-reward.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
